Vutrisiran · AMVUTTRA
RNA / oligonucleotide
Evidence outlook
Approved: Transthyretin Amyloidosis with Cardiomyopathy, Transthyretin Amyloidosis with Polyneuropathy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM)
- Hereditary transthyretin-mediated amyloidosis (hATTR) in adults with stage 1 or stage 2 polyneuropathy
- TTR type familial amyloidosis with polyneuropathy
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04153149 NCT04153149 · Transthyretin Amyloidosis with Cardiomyopathy HELIOS-B randomised 655 patients with transthyretin amyloid cardiomyopathy to vutrisiran or placebo under quadruple masking. Both primary analyses of the clinical composite endpoint (all-cause death and recurrent cardiovascular events) were met: HR 0.718 (p=0.0118) in the overall population and HR 0.672 (p=0.0162) in the monotherapy subgroup. Registry: NCT04153149 | 3 | Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population (Up to Month 36); Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy Subgroup (Up to Month 36) 2024-05-08 | Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other Transthyretin (TTR) drugs
Acoramidis, Eplontersen, Patisiran, Inotersen, Cliramitug and 3 more. Compare all 9 Transthyretin (TTR) drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Vutrisiran (AMVUTTRA): this drug | Approved | RNA / oligonucleotide | Transthyretin (TTR) | Reliable signal | NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 | |
| Acoramidis (Attruby) | Approved | Small molecule | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Cliramitug | Phase 3 | Monoclonal antibody | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Coramitug | Phase 3(overall) | Monoclonal antibody | Transthyretin (TTR) | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Eplontersen (Wainua) | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | Partial signal | NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed | |
| Nexiguran Ziclumeran | Phase 3 | Gene therapy / editing | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication | |
| Nucresiran | Phase 3 | RNA / oligonucleotide | Transthyretin (TTR) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow AMVUTTRA (Vutrisiran) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.